SG Talk

Full Version: China developed diabetes drug highlights biopharma surge

You're currently viewing a stripped down version of our content. View the full version with proper formatting.

Shanghai-based Innogen Pharma is set to shake up the diabetes treatment market with the approval of efsubaglutide alfa, a human-derived, long-acting GLP-1 receptor agonist aimed at adult type 2 diabetes.

https://www.shine.cn/news/in-focus/2502198193/

SG Talk

theold